PharmD Info

A forum for Indian Pharmacy Professionals

Important: Registered today to have the complete access on this forum --- Register Here
Its an inter-professional and collaborative learning platform for the doctors and other healthcare professionals to discuss on various healthcare issues and views with pharmacy professionals. Pharmacist also can assist and share your ideas for the better therapeutic outcomes based on clear evidence. E.g: Drug Information, Decision Analysis and EBM.
Forum rules: The contents of the pharmdinfo.com, such as text, graphics, images, and other material contained on the pharmdinfo.com Site ("Content") are for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on the Pharmdinfo.com Site!

If you think you may have a medical emergency, call your doctor or 108 immediately. pharmdinfo.com does not recommend or endorse any specific tests, physicians, products, procedures, opinions, or other information that may be mentioned on the Site
  • User avatar
User avatar
By Admin
#1910
The emergence of resistance to drugs used to treat tuberculosis (TB), and particularly multidrug-resistant TB (MDR-TB), has become a significant public health problem in a number of countries and an obstacle to effective TB control. In India, the available information from the several drug resistance surveillance studies conducted in the past suggest that the rate of MDR-TB is relatively low in India.

However this translates into a large absolute number of cases and as yet the management of patients with MDR-TB is inadequate. Specific measures are being taken within the Revised National Tuberculosis Control Programme (RNTCP) to address the MDR-TB problem through appropriate management of patients and strategies to prevent the propagation and dissemination of MDR-TB.

Traditionally, DOTS-Plus refers to DOTS programmes that add components for MDR-TB diagnosis, management and treatment. These guidelines promote full integration of DOTS and DOTS-Plus activities under the RNTCP, so that patients with MDR-TB are both correctly identified and properly managed under the recommendations set out in this document.

Finally, the guideline introduces new standards for registering, monitoring and reporting outcomes of multidrug-resistant TB cases. This uniform information management system will allow systematic, consistent data collection and analysis which will facilitate appropriate supervision and monitoring of the DOTS Plus activities and will play an important role in shaping future policies and recommendations.
Attachments
(573.47 KiB) Downloaded 6 times
Similar Topics
Topics Statistics Last post
1 Replies 
1291 Views
by rahmatulla.syed
22 Oct 2017, 10:36
Patient Counselling Guidelines
by Admin  - 02 Dec 2016, 21:35  - In: Pharmaceutical Care
0 Replies 
994 Views
by Admin
02 Dec 2016, 21:35
Dengue fever Treatment Guidelines
by Admin  - 06 Mar 2017, 11:32  - In: Indian Doctors Forum
0 Replies 
1642 Views
by Admin
06 Mar 2017, 11:32
Indian Treatment Guidelines for Malaria
by Admin  - 06 Mar 2017, 11:32  - In: Indian Doctors Forum
0 Replies 
1666 Views
by Admin
06 Mar 2017, 11:32
0 Replies 
811 Views
by Admin
01 Apr 2017, 23:35

Tags

The Pharmacy Council of India (PCI) has launched a[…]

Indian Association of Colleges of Pharmacy. A/C N[…]

PharmD Info Online Group Discussion Disc[…]

PCI chalks out plans to allay concerns of educatio[…]

WELCOME TO OUR E-LEARN COURSE WORK MODULES